Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis.
about
Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectivesAPF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroAntiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic ChemotherapyA phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapyAprepitant and fosaprepitant: a 10-year review of efficacy and safetyA Comparison of 5-HT3 Receptor Antagonist and Metoclopramide in the Patients Receiving Chemotherapeutic Regimens Including CMF, CAF and CHOP.A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting.Relationship between traditional Chinese medicine constitutional types with chemotherapy-induced nausea and vomiting in patients with breast cancer: an observational study.Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy.Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens.Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapyControl of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimensIntegrative review of factors related to the nursing diagnosis nausea during antineoplastic chemotherapy.SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016).Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy.Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.A retrospective study of R-CHOP/CHOP therapy-induced nausea and vomiting in non-Hodgkin's lymphoma patients: a comparison of intravenous and oral 5-HT3 receptor antagonists.Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer.Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy.Changes in the Occurrence, Severity, and Distress of Symptoms in Patients With Gastrointestinal Cancers Receiving Chemotherapy.Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea.A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting.Preliminary evaluation of a predictive blood assay to identify patients at high risk of chemotherapy-induced nausea.Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study.Prevention of chemotherapy-induced vomiting in children receiving multiple-day cisplatin chemotherapy: A hospital-based, retrospective cohort study.Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomitingOlanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective studyCost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy
P2860
Q26744323-A1AFA35B-EF55-4412-A39F-32C5E3158F60Q33734386-44A6590D-B969-4821-AEDC-A2A7715E5CCDQ33820851-7386B35E-2511-4270-A56E-CA2EACD0D537Q35179738-C876061E-3B84-49C8-94F6-6E6297994BE5Q35345557-63FB85D6-7707-4AA3-AF5F-10542262A284Q35543778-52EDC480-6F7C-4EC7-ACFF-F146ED68C1E6Q36068646-781D8EF4-090F-4A41-889F-370AB287725CQ36187964-0579D237-0146-4B5C-8472-38531DE0B615Q36205615-A22A5EEE-CFB8-4AFE-8BD2-0287D37275AEQ36400372-8EFF0EA6-95D3-4C9F-BFC5-76EEFECB49ACQ36478194-DD4ED292-2982-486A-8A5F-89298935D076Q36764931-40AD33DE-D7C7-4171-B282-E0240CD74CB1Q36778149-BD483C24-8798-4E96-BF14-1F7A25BAC661Q37139336-8E780333-190E-40DF-89AE-206D943BDDC0Q37347921-B9555008-9242-46ED-BFCE-59CBBF3139A0Q37475199-147E1E65-8621-4C2B-A163-09C698AE9EA3Q38574240-613E049F-584F-4AE8-8DFE-5FB7538C676CQ38617383-B85DF873-1FAB-4122-9585-CD9AE1BDD03BQ38843951-E8DA5102-0F05-4C37-AF9A-ADE5EC32D3CFQ38894275-5DE0FA4A-21B9-48A3-AABC-3CA3AB494AF4Q39010204-B9C3948B-71F7-44A4-9062-FC6C937D3CBFQ39677350-729B1185-C626-4272-9DAC-9A3712988DF6Q43673718-773F09EE-06F0-44A4-B5C7-3E7901147700Q47572599-53143FBF-0877-4AFA-AC7E-63C7DC29E7D7Q47671686-6C0308DC-0D63-44FE-A809-5D0A20AA2E1BQ47870600-F64F5624-E913-472E-BEEE-B7E3B4D779EAQ48035092-9BCC8589-74BC-4F36-AA06-8B8F5166448AQ48282913-C48F1113-3DF6-4143-B490-331907A2521FQ49570044-25272350-43D7-4C3C-A94A-65CDC14DD2B9Q50227319-3729711E-EB3F-49C2-8C67-66B887A0402EQ53828936-ACE0E2D6-5825-46AC-865B-092241658C14Q54127832-34938AE9-3D3F-4CD9-B957-9E5853D89050Q57483947-5B7D8B99-B4B6-48EF-A207-98D27AD60665Q58618185-CD42A0D6-A162-4032-A538-D975475D2DCFQ58800927-7B1E3832-A8B8-410A-90B9-D3CF4DCE0904
P2860
Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Risk factors of chemotherapy-i ...... alized antiemetic prophylaxis.
@en
Risk factors of chemotherapy-i ...... alized antiemetic prophylaxis.
@nl
type
label
Risk factors of chemotherapy-i ...... alized antiemetic prophylaxis.
@en
Risk factors of chemotherapy-i ...... alized antiemetic prophylaxis.
@nl
prefLabel
Risk factors of chemotherapy-i ...... alized antiemetic prophylaxis.
@en
Risk factors of chemotherapy-i ...... alized antiemetic prophylaxis.
@nl
P2093
P2860
P356
P1433
P1476
Risk factors of chemotherapy-i ...... alized antiemetic prophylaxis.
@en
P2093
Ikuo Sekine
Kaoru Kubota
Toshiaki Saeki
Yoshihiko Segawa
P2860
P304
P356
10.1111/CAS.12146
P577
2013-04-16T00:00:00Z